391 related articles for article (PubMed ID: 24445571)
1. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
Kamal SM; Kassim SK; Ahmed AI; Mahmoud S; Bahnasy KA; Hafez TA; Aziz IA; Fathelbab IF; Mansour HM
Am J Gastroenterol; 2014 Feb; 109(2):199-211. PubMed ID: 24445571
[TBL] [Abstract][Full Text] [Related]
2. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
[TBL] [Abstract][Full Text] [Related]
3. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
Thompson AJ; Muir AJ; Sulkowski MS; Ge D; Fellay J; Shianna KV; Urban T; Afdhal NH; Jacobson IM; Esteban R; Poordad F; Lawitz EJ; McCone J; Shiffman ML; Galler GW; Lee WM; Reindollar R; King JW; Kwo PY; Ghalib RH; Freilich B; Nyberg LM; Zeuzem S; Poynard T; Vock DM; Pieper KS; Patel K; Tillmann HL; Noviello S; Koury K; Pedicone LD; Brass CA; Albrecht JK; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Jul; 139(1):120-9.e18. PubMed ID: 20399780
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
Bizid S; Bouali R; Ouedrani A; Mrabet A; Ben Abdallah H; Ghazouani E; Abdelli N
Tunis Med; 2016 Jan; 94(1):6-11. PubMed ID: 27525598
[TBL] [Abstract][Full Text] [Related]
8. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
9. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
Rivero-Juárez A; Camacho Espejo A; Perez-Camacho I; Neukam K; Caruz A; Mira JA; Mesa P; García-Lázaro M; Torre-Cisneros J; Pineda JA; Rivero A
J Antimicrob Chemother; 2012 Jan; 67(1):202-5. PubMed ID: 21990051
[TBL] [Abstract][Full Text] [Related]
10. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
Halfon P; Bourliere M; Ouzan D; Maor Y; Renou C; Wartelle C; Pénaranda G; Tran A; Botta D; Oules V; Castellani P; Portal I; Argiro L; Dessein A
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):931-5. PubMed ID: 21900787
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.
Rangnekar AS; Fontana RJ
Aliment Pharmacol Ther; 2012 Jul; 36(2):104-14. PubMed ID: 22612303
[TBL] [Abstract][Full Text] [Related]
12. Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis.
El-Fattah MA
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101480. PubMed ID: 32622719
[TBL] [Abstract][Full Text] [Related]
13. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
Sarrazin C; Susser S; Doehring A; Lange CM; Müller T; Schlecker C; Herrmann E; Lötsch J; Berg T
J Hepatol; 2011 Mar; 54(3):415-21. PubMed ID: 21112657
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
15. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.
Bitetto D; Fattovich G; Fabris C; Ceriani E; Falleti E; Fornasiere E; Pasino M; Ieluzzi D; Cussigh A; Cmet S; Pirisi M; Toniutto P
Hepatology; 2011 Apr; 53(4):1118-26. PubMed ID: 21480318
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
Riva E; Scagnolari C; Monteleone K; Selvaggi C; Picardi A; Mazzarelli C; Pizzigallo E; Vincenzi B; Carducci A; Antonaci S; Giannelli G; Antonelli G
J Viral Hepat; 2012 Sep; 19(9):650-3. PubMed ID: 22863269
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection.
Abdelwahab SF; Zakaria Z; Allam WR; Hamdy S; Mahmoud MA; Sobhy M; Rewisha E; Waked I
Arch Virol; 2015 Nov; 160(11):2833-7. PubMed ID: 26280523
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
[TBL] [Abstract][Full Text] [Related]
20. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.
Mangia A; Santoro R; Copetti M; Massari M; Piazzolla V; Spada E; Cappucci G; Missale G; Mottola L; Agostinacchio E; Mauro Ld; Zuccaro O; Maio P; Pellegrini F; Folgori A; Ferrari C
J Hepatol; 2013 Aug; 59(2):221-8. PubMed ID: 23587473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
